Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

ZyCov-D was developed on a DNA platform using a non-replicating and non-integrating plasmid carrying the novel coronavirus gene, making it very safe. In addition, ZyCoV-D is a three-dose, intradermal vaccine, which is applied using The PharmaJet® needle-free system, Tropis®, which can also lead to a significant reduction in any side effects. Also, being a plasmid DNA vaccine, ZyCoV-D doesn’t have any problem associated with vector-based immunity, says the company.

The DNA platform is known to have better vaccine stability and lower cold chain requirements, which would make it easier to store and transport to remote parts of the country. ZyCoV-D is stored at 2-8 C but has shown good stability at temperatures of 25C for at least three months. The thermostability of the vaccine will help in easy transportation and storage of the vaccine and reduce any cold chain breakdown challenges leading to vaccine wastage.